Loading...
Verapamil — Export Intelligence Report
2025-Q4 · TransData Nexus
PHARMA TRADE INTELLIGENCE
INDIA EXPORT INTELLIGENCE REPORT
Verapamil
2025-Q4
Comprehensive analysis of India’s verapamil export trade — suppliers, buyers, prices, routes, and every shipment record.
136
Shipments
$4.10M
Trade Value
30
Suppliers
26
Buyers
19
Countries
Scan for online report
Talk to our analyst: +91 95950 78788
https://transdatanexus.com/pharmaceutical/verapamil
01
PART I — OVERVIEW
Executive Summary
At-a-glance KPIs, key findings, and strategic positioning of India’s verapamil trade — 2025-Q4
KEY TAKEAWAY
Verapamil 2025-Q4 exports total $4.1M across 19 countries, with MYLAN LABORATORIES LTD commanding 43.6% market share.
TOTAL SHIPMENTS
136
2025-Q4
EXPORT VALUE
$4.1M
FOB USD
TOTAL QUANTITY
39.9M
units shipped
INDIAN SUPPLIERS
30
unique exporters
GLOBAL BUYERS
26
unique importers
DESTINATIONS
19
countries
MEDIAN UNIT PRICE
$1.14
per unit
TOP-5 SHARE
95.2%
of total USD
BRANDED SHARE
57.4%
78 shipments
DOSAGE FORMS
8
product types
6 KEY FINDINGS
1
MYLAN LABORATORIES LTD is India's #1 Verapamil exporter with $1.8M (43.6% market share).→ §5, Indian Supplier Rankings
2
Verapamil reached 19 countries, with United States as the top destination ($2.5M).→ §4, Global Destination Map
3
Market concentration is high (HHI: 2784) — top 10 suppliers control 99.8% of exports.→ §5, Indian Supplier Rankings
4
88.5% of buyers (23 of 26) source from a single Indian supplier — potential poaching opportunities.→ §6, Global Buyer Rankings
5
Tablet dominates (67.5%) across 8 dosage forms.→ §7, Price Benchmarks
6
17 countries have ≤5 Indian suppliers — easy-entry markets for SME exporters.→ §9, Strategic Opportunities
WHO THIS REPORT IS FOR
S SUPPLIERS (Indian pharma exporters)
- See which buyers your competitors are shipping to, at what price, through which ports
- Identify buyers that are single-sourced (poaching opportunities)
- Benchmark your pricing and catalog vs the Top 25
B BUYERS (global importers)
- Discover which Indian exporters supply this product and what they sell
- Benchmark the price you are paying vs the market median by country and dosage
- Identify alternative suppliers with proven exports to similar destinations
Figure 1.1 MYLAN LABORATORIES LTD leads in volume — how do 30 exporters compare on price × volume?
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Every bubble is one Indian verapamil exporter. X-axis = shipment count; Y-axis = average unit price; bubble size = total revenue. Dashed lines split at the median — exporters in the top-right (Bulk Leaders) combine high volume with premium pricing.
HOW TO READ THIS REPORT
60 seconds
Scan this page — KPIs, thesis, flagship chart, top findings
5 minutes
Read every Key Takeaway line across §1–§9
30 minutes
Read sections tagged for your role ([S] or [B]) end-to-end
In depth
Drill into §10 for your country · supplier / buyer directories at end
02
PART I — OVERVIEW
About This Report
Data sources, methodology, trust signals, and what this Verapamil report covers
KEY TAKEAWAY
Every figure in this report is grounded in real commercial verapamil trade records. Data comes from official customs filings and public trade sources, runs through a multi-layer quality process, and lands in a clean, consistent report you can rely on.
S FOR SUPPLIERS
Every competitor benchmark, market share figure, and buyer list in this report comes from verified commercial shipments — not surveys or estimates. Use them with confidence when planning your next pitch.
B FOR BUYERS
Every supplier profile, price benchmark, and trade route in this report reflects what that supplier actually ships — real volumes, real destinations, real prices. Use them to qualify and compare Indian verapamil suppliers.
§2.1 Reporting parameters · the scope of this 2025-Q4 Verapamil India trade report
Product scope
Verapamil
All variants merged — branded and generic formulations of verapamil
Time period
2025-Q4
October, November, December 2025 — a single-quarter snapshot
Data sources
Official & public trade records
Government customs filings, public trade databases and licensed commercial feeds
Geography
India origin → global
Indian sea and air ports shipping to destination markets worldwide
Currency
USD (FOB)
Declared Free-on-Board value at the Indian port of loading
Shipments analysed
136
Every commercial verapamil trade record in the period, aggregated and deduplicated
§2.2 Our quality process · Figure 2.1
Figure 2.1 From raw trade records to a clean report — the four quality pillars.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Raw trade data (left) flows through four quality checks — source verification, format standardisation, entity matching, and deduplication — to produce the clean, reliable data (right) behind every chart and table in this report.
§2.3 Trust signals · what you can rely on in the numbers you read
DATA COVERAGE
10M+
Pharmaceutical trade records across the full TransData Nexus platform.
COUNTRIES
150+
Origin and destination countries covered in the global pharma trade database.
DATA ACCURACY
99.9%
Validation rate on core fields — supplier, buyer, product, quantity, value.
UPDATE FREQUENCY
Daily
Platform refresh cadence. This report is a snapshot from the same live data.
§2.4 Limitations · what the data does and does not tell you
WHAT THIS DATA DOES AND DOES NOT SAY
- Prices are at the Indian port of loading (FOB), not the final delivered cost in the destination country. Freight, insurance, import duty and local margin are not included.
- This is a single-quarter snapshot. Multi-quarter trends, year-over-year growth and historical comparisons are available on the full platform.
- A small number of records have incomplete transport mode or destination port fields; these appear blank in the shipment register but are still counted in totals.
- This report is a commercial intelligence tool, not a legal audit. For high-stakes decisions, cross-reference with the underlying trade records via the full platform.
03
PART II — MARKET STRUCTURE
Quarterly Trade Overview
Monthly trends, regional performance, and ranking shifts — 2025-Q4
KEY TAKEAWAY
2025-Q4 followed a steady rise: Oct $347.8K, Nov $1.7M, Dec $2.0M. Shipment counts rose across the quarter.
S FOR SUPPLIERS
Track which months your competitors were most active, which destinations rose or fell, and whether the Nov dip hit your segment. The bump charts show rank movement — watch for rivals climbing past you.
B FOR BUYERS
Identify whether your current Indian supplier maintained steady shipments through the quarter, or whether they pulled back. Steady suppliers during dips signal reliable partnerships.
1
$347.8K
Oct USD
8 shipments
2
$1.7M
Nov USD
+394.7% MoM
3
$2.0M
Dec USD
+17.9% MoM
4
Steady rise
Q4 growth shape
Oct → Nov → Dec
Fig 3.1 Nov rose 394.7% in USD but shipment count kept climbing.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Blue bars = monthly USD. Orange line = shipment count. When bars drop but line rises, average shipment value fell. Insight: Oct opened at $348K, making it the weakest month by value.
Fig 3.2 Q4 cumulative USD reached $4.1M.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: The curve shows the running total across the quarter. A steeper slope means that month contributed more revenue. Insight: The curve’s steepest section reveals which month drove the most trade value.
Fig 3.3 $1.4M rise in Nov, $308K recovery in Dec.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Blue bars = absolute monthly value. Red = month-over-month loss; green = gain. Insight: Trade grew steadily across the quarter.
Fig 3.4 Regional breakdown by month — which corridors swung most?
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each coloured layer is one destination region. Layer height = USD in that month. Insight: The top region contributed the most, while the smallest region had the least volume.
§3.1 Monthly summary
| Oct | $348K | 8 shipments |
| Nov | $1.7M | 51 shipments |
| Dec | $2.0M | 77 shipments |
| Q4 Total | $4.1M | 136 shipments |
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
Fig 3.5 Top 10 destination countries by monthly USD rank — who’s rising?
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each line traces a country’s monthly rank. Lines crossing = rank swaps. Insight: United States held #1 throughout the quarter.
Fig 3.6 Top 10 Indian exporters by monthly USD rank.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each line traces a supplier’s monthly rank. Flat = stable position; crossing = rank change. Insight: MYLAN LABORATORIES LTD maintained its leading position.
04
PART II — MARKET STRUCTURE
Global Destination Map
Which countries import verapamil from India, how much they buy, and who supplies each market
KEY TAKEAWAY
United States absorbs 62.0% of India’s 2025-Q4 verapamil trade ($2.5M). Beyond the top 10 destinations, 17 countries have fewer than 5 Indian suppliers each — white-space markets where new entrants face minimal competition. Asia has 6 destination countries, the widest regional diversity.
S FOR SUPPLIERS
Use the flow map and lanes table to see which destinations your competitors dominate. For small and mid-size suppliers: look beyond the leading markets — the 17 countries in the long tail have fewer than 5 Indian suppliers each and low competitive barriers.
B FOR BUYERS
Find your country on the map to see how much verapamil India ships to your market, who the top suppliers are, and whether you’re in a concentrated or competitive corridor.
Asia
$451K
11.0% of trade
6 countries · 49 shipments
Europe
$1.1M
26.7% of trade
2 countries · 12 shipments
Americas
$2.5M
62.2% of trade
4 countries · 58 shipments
Africa
$434
0.0% of trade
5 countries · 12 shipments
Oceania
$4K
0.1% of trade
2 countries · 5 shipments
Fig 4.1 United States is the #1 corridor ($2.5M) — 19 flow arcs from India radiate across 5 continents.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: The world map shows every country colored by how much Indian verapamil it receives (light = low, dark = high). Orange arcs radiate from India to the top 19 destinations; arc thickness = USD value. All destinations are labeled with country name + USD.
§4.1 Top 10 bilateral trade lanes (India → destination) with top Indian suppliers
| # | Destination | Total USD | Ships | #1 Indian supplier | USD | #2 Indian supplier | USD | #3 Indian supplier | USD |
|---|---|---|---|---|---|---|---|---|---|
| 1 | United States | $2.5M | 43 | GLENMARK PHARMACEUTICALS LTD | $1.0M | MYLAN LABORATORIES LTD | $687K | CADILA PHARMACEUTICALS LTD | $528K |
| 2 | France | $912K | 10 | MYLAN LABORATORIES LTD | $912K | — | — | — | — |
| 3 | Turkmenistan | $324K | 2 | THRIVE THERAPEUTIC PVT LTD | $324K | — | — | — | — |
| 4 | Netherlands | $182K | 2 | MYLAN LABORATORIES LTD | $182K | — | — | — | — |
| 5 | Saudi Arabia | $126K | 9 | ZYDUS LIFESCIENCES LTD | $120K | MYGENIC HEALTHCARE PVT LTD | $5K | SONIA LABORATORY PVT LTD | $590 |
| 6 | Barbados | $8K | 13 | MCARE IMPEX PVT LTD | $7K | DRIVECURE HEALTHCARE PVT LTD | $605 | — | — |
| 7 | Australia | $4K | 4 | MYLAN LABORATORIES LTD | $4K | — | — | — | — |
| 8 | Venezuela | $1K | 1 | KWALITY PHARMACEUTICALS LTD | $1K | — | — | — | — |
| 9 | United Arab Emirates | $470 | 35 | DERRIC WOOD | $256 | DROPS PHARMA PVT LTD | $133 | ZYPHARS PHARMACEUTICS PVT LTD | $56 |
| 10 | New Zealand | $389 | 1 | MYLAN LABORATORIES LTD | $389 | — | — | — | — |
Table 4.1 — Top 10 destination countries ranked by trade value, with the largest Indian suppliers for each market.
Fig 4.2 Asia leads at 11.0% of USD — but United States is the single largest market.
Region → country treemap
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Column width = region USD share. Within each column, cells are stacked by country, height = share within region.
§4.2 Destination concentration
62.0%
#1 country share
United States alone
99.7%
Top 5 share
5 of 19 countries
100.0%
Top 15 share
Long tail of 4 countries = 0.0%
HHI 4428
Destination HHI
Highly concentrated
19
Countries served
Global pharma reach from India
6
Asia countries
Widest regional diversity
Source: TransData Nexus trade data platform
05
PART III — WHO’S IN THIS MARKET
Indian Supplier Rankings & Profiles
30 Indian exporters ranked by value — profiles, portfolios, and competitive intelligence
KEY TAKEAWAY
MYLAN LABORATORIES LTD ($1.8M, 43.6% share) and GLENMARK PHARMACEUTICALS LTD ($1.0M) together control 68.4% of India’s 2025-Q4 verapamil trade. The top 5 suppliers hold 95.2%. 30 companies shipped at least once.
S FOR SUPPLIERS
Find your rank, your competitors’ ranks, and the gap in USD/share between you. The profile pages show each top supplier’s buyer portfolio, dosage mix and route map — your competitive-intelligence toolkit.
B FOR BUYERS
Find potential Indian verapamil suppliers ranked by size, catalog breadth and destination reach. The profile pages reveal which suppliers have proven trade lanes to your region.
Fig 5.1 MYLAN LABORATORIES LTD leads by $770K over GLENMARK PHARMACEUTICALS LTD — top 20 Indian exporters ranked by trade value
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each bar = one Indian supplier ranked by USD. The (#N) shows their rank by shipment count — mismatches reveal pricing strategy. Insight: DERRIC WOOD is #17 by value but #1 by volume.
Fig 5.2 DERRIC WOOD also leads by shipment count (27) but ranking shifts for volume-heavy players
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Same suppliers re-ranked by shipment count. The (#N) shows their rank by USD value. Insight: DERRIC WOOD moves from #1 by volume to #17 by value — fewer but higher-value shipments.
05
PART III — WHO’S IN THIS MARKET
Supply Landscape — Archetypes & Concentration
How India’s 30 verapamil suppliers split into strategic segments
KEY TAKEAWAY
8 suppliers (25%) generate 99.5% of total trade value. The market splits into four archetypes: Market Leaders, High-Value specialists, Volume players, and a long tail.
Fig 5.3 MYLAN LABORATORIES LTD and GLENMARK PHARMACEUTICALS LTD sit in the leaders zone — high volume AND high value.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each bubble is one Indian supplier. X-axis = shipment count (log scale); Y-axis = total USD value (log scale); bubble size = revenue. Blue dashed lines split at the median. Market Leaders (top-right) combine high volume with high value. Premium Niche (top-left) ship fewer but higher-value consignments. Volume Players (bottom-right) compete on quantity. Long-Tail (bottom-left) are small or occasional exporters. Conclusion: the log scale reveals clear strategic clusters — use this map to identify where your company sits relative to competitors.
Fig 5.4 25% of suppliers = 99.5% of USD — classic concentration.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Top bar = supplier %, bottom bar = USD %. The gap = market concentration.
Product variety — how many formulations each supplier ships
| # | Supplier | Dosage forms | Countries | USD |
|---|---|---|---|---|
| 1 | MYLAN LABORATORIES LTD | 2 | 5 | $1.8M |
| 2 | MCARE IMPEX PVT LTD | 2 | 1 | $7K |
| 3 | DROPS PHARMA PVT LTD | 2 | 2 | $504 |
| 4 | DERRIC WOOD | 2 | 1 | $256 |
| 5 | GLENMARK PHARMACEUTICALS LTD | 1 | 1 | $1.0M |
| 6 | CADILA PHARMACEUTICALS LTD | 1 | 1 | $528K |
| 7 | THRIVE THERAPEUTIC PVT LTD | 1 | 1 | $324K |
| 8 | ZYDUS LIFESCIENCES LTD | 1 | 2 | $246K |
| 9 | MANKIND PHARMA LTD | 1 | 1 | $70K |
| 10 | SOMERSET THERAPEUTICS PVT LTD | 1 | 1 | $59K |
Table 5.1 — The more dosage forms a supplier ships, the more versatile their manufacturing capability.
05
PART III — WHO’S IN THIS MARKET
Supply Landscape — India Origin Geography & Concentration
Which Indian cities and states are the verapamil manufacturing hubs
KEY TAKEAWAY
Ahmedabad and Aurangabad together account for $1.5M of India’s 2025-Q4 verapamil trade.
Fig 5.5 Ahmedabad (3 exporters, $774K) and Aurangabad (1 exporters, $734K) are India’s verapamil capitals.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Orange bubbles mark major pharma hub cities; bubble size = USD value. Every hub labeled.
§5.1 Supplier concentration metrics
95.2%
Top 5 share
5 of 30 suppliers
99.8%
Top 10 share
10 of 30 suppliers
99.5%
Top 25% share
8 suppliers = 100% USD
HHI 2784
Supplier HHI
Concentrated
30
Total suppliers
shipped Verapamil in 2025-Q4
20+ cities
Indian hubs
Ahmedabad and Aurangabad lead
§5.2 Coming next: 1 exporter deep-dive profiles
Each of the top 1 suppliers gets a dedicated 2-page profile with:
- 6 KPI cards — trade value, shipments, countries, buyers, avg ship value, branded share
- Dosage form breakdown — what formulations they ship
- Monthly trend — Oct / Nov / Dec trajectory
- Trade flow map — supplier → country → importer connections
- Buyer portfolio with lock-in analysis
SUPPLIER PROFILES IN THIS REPORT
| #1 | MYLAN LABORATORIES LTD | $1.8M |
#1
EXPORTER PROFILE #1 OF 1
MYLAN LABORATORIES LTD
Aurangabad · India’s #1 verapamil supplier by USD · 2025-Q4
2025-Q4 USD
$1.8M
43.6% market share
SHIPMENTS
24
avg $74K/ship
COUNTRIES
5
destination markets
BUYERS
5
4 single-sourced
BRANDED
67%
of shipments
DOSAGE FORMS
2
product types
TOP 5 DESTINATIONS
France is the #1 market at $912K (51% of trade), followed by United States at $687K. 5 countries served.
| # | Country | USD | Ships | Share |
|---|---|---|---|---|
| 1 | France | $912K | 10 | 51.1% |
| 2 | United States | $687K | 7 | 38.5% |
| 3 | Netherlands | $182K | 2 | 10.2% |
| 4 | Australia | $4K | 4 | 0.2% |
| 5 | New Zealand | $389 | 1 | 0.0% |
MONTHLY TREND
Nov peaked at $1.2M. Oct was the weakest at $0.
PRODUCT MIX
Tablet dominates at 51% of trade. Capsule (38.5%) and Unknown are secondary formulations.
TOP BUYERS · 4/4 LOCKED IN
4 of 4 buyers source exclusively from this supplier — high lock-in with low competitive threat.
| Buyer | Country | USD | Status |
|---|---|---|---|
| Undisclosed buyer | France | $912K | N/A |
| MYLAN PHARMACEUTICALS … | United States | $687K | ⚠ Locked |
| BGP PRODUCTS GMBH | Netherlands | $182K | ⚠ Locked |
| VIATRIS PTY LTD | Australia | $4K | ⚠ Locked |
| VIATRIS LTD | New Zealand | $389 | ⚠ Locked |
#1
EXPORTER PROFILE #1 OF 1 — TRADE FLOW MAP
MYLAN LABORATORIES LTD — Supplier → Country → Importer
5 destination countries, top 5 importers per country
Fig 5.P1.3 France absorbs $912K — the thickest ribbon.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Left = Indian supplier. Middle = destination countries (ordered by USD). Right = importers within each country. Ribbon thickness = USD value; color = country. Every node labeled with name + USD + ships. Showing top 5 destinations and up to 1 importers per destination.
06
PART III — WHO’S IN THIS MARKET
Global Buyer Rankings & Intelligence
26 importers across 19 countries — who is buying Indian verapamil and how much
KEY TAKEAWAY
The demand side is dramatically more fragmented than supply: the top 24 importers together hold only 68.5% of total USD. 88% of buyers source from a single Indian supplier — a vast pool of lock-in candidates.
S FOR SUPPLIERS
Find the importers buying from your competitors. The rankings reveal who has volume, who pays well, and who sources from multiple Indian suppliers (potential pitch targets).
B FOR BUYERS
See where you rank among global importers of Indian verapamil. Compare your USD and shipment count against peers in your country and dosage segment.
Fig 6.1 GLENMARK PHARMACEUTICALS INC is the #1 importer at $983K (24.0%) — top 24 by trade value
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each bar = one global importer ranked by USD.
Fig 6.2 Re-ranked by shipment count — compare with Fig 6.1 for divergences
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Same 24 importers re-ranked by shipment count.
§6.1 Sourcing diversity — how many Indian suppliers does each buyer use?
88%
Single-source
23 buyers rely on exactly 1 Indian supplier
4%
Dual-source
1 buyers use 2 Indian suppliers
0%
Multi-source (3–4)
0 buyers diversified across 3–4
8%
Broad-source (5+)
2 buyers with 5+ Indian suppliers
06
PART III — WHO’S IN THIS MARKET
Single-Source Buyers & Price Benchmark
Lock-in opportunities grouped by country + where each buyer sits on the price spectrum
KEY TAKEAWAY
These importers source verapamil from exactly one Indian supplier. For each one, the table shows the incumbent, price, and dosage.
S FOR SUPPLIERS
This is your target list. Each row is a buyer locked into one competitor. Offer 5–10% better pricing to win the second-source slot.
B FOR BUYERS
If you see your company here, you are fully dependent on one Indian supplier. Consider qualifying a second source.
§6.2 Single-source lock-in by country
United States 5 single-source buyers
| Importer | Current supplier | USD | Unit $ | Dosage |
|---|---|---|---|---|
| GLENMARK PHARMACEUTICA… | GLENMARK PHARMACEUTI… | $983K | $4.782 | Tablet |
| MYLAN PHARMACEUTICALS … | MYLAN LABORATORIES LTD | $687K | $0.089 | Capsule |
| LIFESCIENCE LOGISTICS | CADILA PHARMACEUTICA… | $528K | $0.041 | — |
| EVERSANA LIFE SCIENCE … | ZYDUS LIFESCIENCES LTD | $126K | $1.598 | Injection |
| LIFESTAR PHARMA LLC | MANKIND PHARMA LTD | $70K | $13.579 | Injection |
United Arab Emirates 4 single-source buyers
| Importer | Current supplier | USD | Unit $ | Dosage |
|---|---|---|---|---|
| EMIRATES POST COMPANY | DERRIC WOOD | $255.821 | $0.941 | Tablet |
| MEDISUITE MEDICAL STORE | MEDEX PHARMACEUTICALS | $12.246 | $0.245 | Injection |
| EMIRATES POST GROUP | CLOVERLEAF ECOM PVT … | $8.865 | $0.521 | — |
| BEST INTERNATIONAL FZE | MEDEX PHARMACEUTICALS | $3.996 | $0.200 | Injection |
Saudi Arabia 2 single-source buyers
| Importer | Current supplier | USD | Unit $ | Dosage |
|---|---|---|---|---|
| QOMEL COMPANY | ZYDUS LIFESCIENCES LTD | $120K | $3.062 | Injection |
| AL MAAYER ALASRYAH COM… | SONIA LABORATORY PVT… | $590.474 | $0.197 | Injection |
Netherlands 1 single-source buyers
| Importer | Current supplier | USD | Unit $ | Dosage |
|---|---|---|---|---|
| BGP PRODUCTS GMBH | MYLAN LABORATORIES LTD | $182K | $0.075 | Tablet |
Australia 1 single-source buyers
| Importer | Current supplier | USD | Unit $ | Dosage |
|---|---|---|---|---|
| VIATRIS PTY LTD | MYLAN LABORATORIES LTD | $4K | $0.0009 | Tablet |
§6.3 Price positioning — top 24 importers
| # | Importer | Country | USD | $/ship | Tier |
|---|---|---|---|---|---|
| 1 | GLENMARK PHARMACEUTI… | United States | $983K | $52K | Premium |
| 2 | MYLAN PHARMACEUTICAL… | United States | $687K | $98K | Premium |
| 3 | LIFESCIENCE LOGISTICS | United States | $528K | $106K | Premium |
| 4 | BGP PRODUCTS GMBH | Netherlands | $182K | $91K | Premium |
| 5 | EVERSANA LIFE SCIENC… | United States | $126K | $126K | Premium |
| 6 | QOMEL COMPANY | Saudi Arabia | $120K | $120K | Premium |
| 7 | LIFESTAR PHARMA LLC | United States | $70K | $23K | Mid |
| 8 | RX CROSSROADS 3PL LLC | United States | $52K | $17K | Mid |
| 9 | AVET PHARMACEUTICALS… | United States | $51K | $51K | Premium |
| 10 | VIATRIS PTY LTD | Australia | $4K | $906.000 | Budget |
| 11 | ACTAVIS LLC | United States | $2K | $1K | Budget |
| 12 | LABORATORIOS REMENY,… | Venezuela | $1K | $1K | Budget |
| 13 | TO THE INVOICE RAISE… | Barbados | $605.215 | $605.000 | Budget |
| 14 | AL MAAYER ALASRYAH C… | Saudi Arabia | $590.474 | $590.000 | Budget |
| 15 | TO THE CONSIGNEE | United Arab Emirates | $443.850 | $89.000 | Budget |
| 16 | VIATRIS LTD | New Zealand | $389.194 | $389.000 | Budget |
| 17 | EMIRATES POST COMPANY | United Arab Emirates | $255.821 | $9.000 | Budget |
| 18 | IMPERIAL PHOENIX CO … | Myanmar | $246.742 | $247.000 | Budget |
| 19 | CM STAR CORP | Philippines | $207.682 | $208.000 | Budget |
| 20 | CENTRAL MEDICAL STOR… | Montserrat | $113.669 | $114.000 | Budget |
| 21 | REGENCY EXIM TRADE LTD | Mauritius | $15.431 | $8.000 | Budget |
| 22 | MEDISUITE MEDICAL ST… | United Arab Emirates | $12.246 | $12.000 | Budget |
| 23 | EMIRATES POST GROUP | United Arab Emirates | $8.865 | $4.000 | Budget |
| 24 | BEST INTERNATIONAL FZE | United Arab Emirates | $3.996 | $4.000 | Budget |
06
PART III — WHO’S IN THIS MARKET
Market Relationship Map
The top 20 × 20 supplier ↔ buyer network as a circular flow diagram
Fig 6.3 MYLAN LABORATORIES LTD → GLENMARK PHARMACEUTICALS INC is the strongest relationship.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Left semicircle = top 20 Indian suppliers; right = top 20 global buyers. Arc length = total USD; colored ribbons = individual relationships, thickness = USD value. Insight: follow the thickest ribbons to identify the dominant trading pairs.
07
PART IV — MARKET BEHAVIOR
Price Benchmarks & Analysis
How Indian verapamil prices vary by supplier, country and dosage form
KEY TAKEAWAY
Verapamil prices span 26614× ($0.0009 → $22.73). The coefficient of variation is 1.44. Dosage form, not destination, is the primary price driver.
S FOR SUPPLIERS
Use the box plot to see where your product sits on the price spectrum. The tornado chart shows exactly where you sit relative to the market median.
B FOR BUYERS
Use this section to benchmark the price you pay against the market. The percentile strip tells you if your current supplier is charging you premium, mid-market or budget rates.
§7.1 Price distribution · Table 7.1
| Statistic | Value | Interpretation |
|---|---|---|
| Min | $0.0009 | Lowest observed unit price |
| P5 | $0.0018 | 5th percentile |
| P25 | $0.077 | 25th percentile (Q1) |
| Median | $1.00 | 50th percentile (Q2) |
| P75 | $6.66 | 75th percentile (Q3) |
| P95 | $17.30 | 95th percentile |
| Max | $22.73 | Highest observed unit price |
| Mean | $4.47 | Arithmetic average |
| CV | 144% | Coefficient of variation (std/mean) |
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
Fig 7.1 SUNNY PHARMA prices at $22.73/unit vs market median $1.00.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each bar shows one supplier’s average unit price relative to the market median (dashed line). Red = above median (premium), green = below (budget).
COMMODITY KINGS
high volume · low unit price
Bulk API/tablet. Largest absolute USD despite lowest per-unit prices. e.g. MYLAN LABORATORIES LTD Sourcing: best for cost-driven procurement.
BULK LEADERS
high volume · premium price
Branded-generic leaders, above-median pricing. e.g. GLENMARK PHARMACEUTICALS LTD Sourcing: hardest to displace; compete on relationship.
LONG-TAIL
low volume · low unit price
Spot/opportunistic players. e.g. KWALITY PHARMACEUTICALS LTD Sourcing: first to approach for new tenders.
PREMIUM NICHE
low volume · premium price
Sterile injectables and infusions. Hospital-grade. e.g. STERIL-GENE LIFE SCIENCES Sourcing: expect 10× price vs tablet.
07
PART IV — MARKET BEHAVIOR
Price Benchmarks & Analysis
Outlier forensics and the procurement cheat sheet — what to expect to pay by country × dosage
KEY TAKEAWAY
Extreme prices are real: the highest are specialty/sterile formulations; the lowest are bulk API. The cheat sheet matrix is the take-home reference for procurement teams.
§7.2 Outlier forensics — top 10 highest and 10 lowest unit prices
↑ TOP 10 HIGHEST USD/UNIT
| Date | Exporter | Country | Dosage | Qty | USD | $/unit | Why |
|---|---|---|---|---|---|---|---|
| Nov 2025 | MANKIND PHARMA LTD | United States | Injection | 1K | $37K | $29.44 | Sterile formulation premium |
| Dec 2025 | SUNNY PHARMA | Montserrat | Tablet | 5 | $113.67 | $22.73 | Specialty / small-batch |
| Oct 2025 | GLENMARK PHARMAC… | United States | Tablet | 6K | $110K | $17.81 | Specialty / small-batch |
| Oct 2025 | GLENMARK PHARMAC… | United States | Tablet | 4K | $73K | $17.73 | Specialty / small-batch |
| Oct 2025 | GLENMARK PHARMAC… | United States | Tablet | 2K | $36K | $17.59 | Specialty / small-batch |
| Dec 2025 | MCARE IMPEX PVT … | Barbados | Tablet | 17 | $294.06 | $17.30 | Specialty / small-batch |
| Dec 2025 | MCARE IMPEX PVT … | Barbados | prolonged release tablets | 17 | $294.06 | $17.30 | Specialty / small-batch |
| Dec 2025 | MCARE IMPEX PVT … | Barbados | Tablet | 17 | $294.06 | $17.30 | Specialty / small-batch |
| Dec 2025 | MCARE IMPEX PVT … | Barbados | Tablet | 17 | $294.06 | $17.30 | Specialty / small-batch |
| Dec 2025 | MCARE IMPEX PVT … | Barbados | Tablet | 65 | $1K | $17.30 | Specialty / small-batch |
↓ TOP 10 LOWEST USD/UNIT
| Date | Exporter | Country | Dosage | Qty | USD | $/unit | Why |
|---|---|---|---|---|---|---|---|
| Dec 2025 | HEMS ( INDIA ) | Maldives | Tablet | 90 | $0.141 | $0.0016 | Bulk generic tablet |
| Dec 2025 | RMPL PHARMA LLP | Saudi Arabia | Injection | 4K | $7.05 | $0.0017 | Sterile formulation premium |
| Dec 2025 | BARAKAH BIOHEALT… | Saudi Arabia | Injection | 2K | $3.99 | $0.0020 | Sterile formulation premium |
| Dec 2025 | VEA IMPEX (I) PV… | Somalia | Other | 1K | $2.51 | $0.0025 | |
| Dec 2025 | VEA IMPEX (I) PV… | Somalia | 2ML | 1K | $2.51 | $0.0025 | |
| Dec 2025 | VEA IMPEX (I) PV… | Somalia | Solution | 1K | $2.51 | $0.0025 | |
| Dec 2025 | VEA IMPEX (I) PV… | Somalia | Solution | 1K | $2.51 | $0.0025 | |
| Dec 2025 | DERRIC WOOD | United Arab Emirates | Tablet | 6 | $0.033 | $0.0055 | Bulk generic tablet |
| Dec 2025 | DERRIC WOOD | United Arab Emirates | Tablet | 6 | $0.055 | $0.0092 | Bulk generic tablet |
| Dec 2025 | DERRIC WOOD | United Arab Emirates | Tablet | 12 | $0.111 | $0.0092 | Bulk generic tablet |
§7.3 Procurement cheat sheet — median USD/unit by country × dosage
Fig 7.2 Median unit price by country × dosage form — darker cells = higher prices.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each cell shows the median price per unit for that country-dosage combination. Dark blue = expensive, light = cheap. Blank cells = no shipments in that combination.
NEGOTIATION RANGE
Use each cell value as the anchor price. Typical dynamics:
- Budget buyer: anchor − 10–15% (floor = cost + freight)
- Mid-market: anchor ± 5–10%
- Premium/tender: anchor + 10–25% (regulated, quality premium)
- Injection/infusion: always 4–10× the tablet price
KEY TAKEAWAYS
- Dosage form is the #1 price driver, not destination
- Light cells = easy-entry markets for small suppliers
- Dark cells = premium markets requiring regulatory investment
08
PART IV — MARKET BEHAVIOR
Shipping Ports & Trade Routes
Which Indian ports ship verapamil, which global ports receive it, and which corridors are high-value vs bulk
KEY TAKEAWAY
Verapamil leaves India through 9+ ports. The top 5 (MUMBAI AIR (SAHAR), NHAVA SHEVA SEA (JNPT), AHMEDABAD AIR) handle 98.5% of total USD. AIR moves 84% of shipments.
S FOR SUPPLIERS
Use the dumbbell to classify your port as high-value hub or bulk workhorse. Note the short-sea routes — Bangladesh, Sri Lanka, Myanmar and East Africa are the easiest logistics corridors for first-time exporters.
B FOR BUYERS
Use the destination port ranking to find which Indian ports serve your market. The lead-time estimates tell you what transit time to expect.
Fig 8.1 MUMBAI AIR (SAHAR) handles $1.9M — top 9 Indian origin ports by trade value.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each bar = one Indian port. Bar length = USD value. The largest ports handle the majority of trade.
Fig 8.2 LYON is the #1 global destination port — top 25 by USD value.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each bar = one destination port worldwide. Bar length = USD value received from India.
§8.1 Reference transit times for key India → global corridors
| Route | Mode | Transit time | Notes |
|---|---|---|---|
| NHAVA SHEVA SEA (JNPT) → US East Coast | Sea | 22–28 days | Via Suez; 2–3 transshipments typical |
| NHAVA SHEVA SEA (JNPT) → Lagos (Nigeria) | Sea | 18–24 days | Direct liner service available |
| MUMBAI AIR (SAHAR) → New York JFK | Air | 3–5 days | Direct cargo; cold-chain available |
| MUNDRA SEA → Rotterdam | Sea | 20–26 days | Via Suez; Hamburg also served |
| HYDERABAD AIR → London Heathrow | Air | 2–4 days | Pharma-grade cargo corridor |
| CHENNAI SEA → Chittagong (Bangladesh) | Sea | 7–12 days | Short-sea route; high frequency |
| RAXAUL → Birgunj (Nepal) | Road | 1–2 days | Land border crossing |
| NHAVA SHEVA SEA (JNPT) → Mombasa (Kenya) | Sea | 14–20 days | Direct or via Colombo hub |
Table 8.1 — Reference times based on standard shipping corridors. Air = 2–5 days; sea = 7–28 days; road = 1–2 days. Add 3–7 days for customs clearance at destination.
08
PART IV — MARKET BEHAVIOR
Shipping Ports & Trade Routes
Trade corridors — origin port to mode of transport to destination region
KEY TAKEAWAY
AIR dominates at 84% of shipments. The alluvial traces every dollar from Indian origin port through transport mode to destination region.
AIR
$3.1M
74.7% of USD · 83.8% of ships
SEA
$991K
24.2% of USD · 14.7% of ships
ICD
$44K
1.1% of USD · 1.5% of ships
Fig 8.3 The dominant corridor is MUMBAI AIR (SAHAR) → Air → Europe ($1.1M).
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Left = Indian origin ports. Middle = transport mode. Right = destination region. Ribbon thickness = USD value; color = mode. Follow the thickest ribbons to find the highest-value corridors.
09
PART V — ACTION
Strategic Opportunities & Action Plan
Market concentration, supply-chain risk, and the dependency patterns that signal where to act
KEY TAKEAWAY
France is the most concentrated destination (HHI 10000, 1 suppliers). United States is the most competitive (HHI 2807).
S FOR SUPPLIERS
The HHI barbell shows where competitors have locked up a market (concentrated = poaching opportunity) vs where you must compete on quality (fragmented). The slope chart reveals who is gaining ground.
B FOR BUYERS
The HHI barbell tells you whether your country has enough supplier options. If concentrated (red zone), you have fewer alternatives.
Fig 9.1 France (HHI 10,000) is the most concentrated — United States (HHI 2,807) is the most competitive.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
What is HHI? The Herfindahl-Hirschman Index measures how concentrated a market is among its suppliers. It ranges from 0 to 10,000. Below 1,500 (green zone) = many suppliers compete openly — healthy, competitive market with low risk. 1,500–2,500 (yellow zone) = a few suppliers hold significant share — moderate concentration. Above 2,500 (red zone) = one or two suppliers dominate the market — high risk for buyers who may lose supply, and hard to break into for new suppliers. Conclusion: 19 of 19 destination markets are concentrated (red zone). 0 are competitive (green zone). Buyers in red-zone markets should urgently qualify a second Indian supplier to reduce dependency risk.
§9.1 Single-source dependencies
| Buyer | Country | Sole supplier | USD | Ships | Risk |
|---|---|---|---|---|---|
| GLENMARK PHARMACEUTI… | United States | GLENMARK PHARMAC… | $983K | 19 | CRITICAL |
| MYLAN PHARMACEUTICAL… | United States | MYLAN LABORATORI… | $687K | 7 | CRITICAL |
| LIFESCIENCE LOGISTICS | United States | CADILA PHARMACEU… | $528K | 5 | CRITICAL |
| BGP PRODUCTS GMBH | Netherlands | MYLAN LABORATORI… | $182K | 2 | HIGH |
| EVERSANA LIFE SCIENC… | United States | ZYDUS LIFESCIENC… | $126K | 1 | HIGH |
| QOMEL COMPANY | Saudi Arabia | ZYDUS LIFESCIENC… | $120K | 1 | HIGH |
| LIFESTAR PHARMA LLC | United States | MANKIND PHARMA LTD | $70K | 3 | MEDIUM |
| RX CROSSROADS 3PL LLC | United States | SOMERSET THERAPE… | $52K | 3 | MEDIUM |
Conclusion: 23 buyers depend on exactly one Indian supplier, representing $2.8M in trade. 3 are rated CRITICAL — if their sole supplier fails, they have no backup. For suppliers: each row is a competitor’s locked-in customer you can target.
§9.2 Multi-source resilience
| Buyer | Country | Suppliers | USD | Dominant | Resilience |
|---|
Conclusion: 0 of these buyers have HIGH resilience (3+ active suppliers). These are the hardest accounts to win but safest partners for long-term contracts.
09
PART V — ACTION
Strategic Opportunities & Action Plan
Market entry playbook and risk landscape by destination country
KEY TAKEAWAY
15 target markets with specific entry approaches. Large suppliers: focus on regulated Tier 1 markets. Small/mid-size: start with Tier 2–3 (low barrier, growing demand).
§9.3 Sourcing recommendations · Table 9.1
| Country | Tier | Lead | Price | Risk | Entry approach |
|---|---|---|---|---|---|
| United States | Tier 3 (emerging) | 3–5 days (air) | $1–$10/unit | LOW | First-mover advantage |
| France | Tier 3 (emerging) | 3–5 days (air) | $0.01–$0.10/unit | LOW | First-mover advantage |
| Turkmenistan | Tier 3 (emerging) | 3–5 days (air) | $1–$10/unit | LOW | First-mover advantage |
| Netherlands | Tier 3 (emerging) | 3–5 days (air) | $0.01–$0.10/unit | LOW | First-mover advantage |
| Saudi Arabia | Tier 3 (emerging) | 3–5 days (air) | $0.10–$1/unit | LOW | First-mover advantage |
| Barbados | Tier 3 (emerging) | 3–5 days (air) | $1–$10/unit | LOW | First-mover advantage |
| Australia | Tier 3 (emerging) | 3–5 days (air) | $0.01–$0.10/unit | LOW | First-mover advantage |
| Venezuela | Tier 3 (emerging) | 3–5 days (air) | $0.01–$0.10/unit | LOW | First-mover advantage |
| United Arab Emirates | Tier 3 (emerging) | 3–5 days (air) | $1–$10/unit | LOW | First-mover advantage |
| New Zealand | Tier 3 (emerging) | 3–5 days (air) | $0.01–$0.10/unit | LOW | First-mover advantage |
| Chad | Tier 3 (emerging) | 3–5 days (air) | $0.10–$1/unit | LOW | First-mover advantage |
| Myanmar | Tier 3 (emerging) | 14–28 days (sea) | $0.10–$1/unit | LOW | First-mover advantage |
| Philippines | Tier 3 (emerging) | 3–5 days (air) | $0.10–$1/unit | LOW | First-mover advantage |
| Montserrat | Tier 3 (emerging) | 3–5 days (air) | $1–$10/unit | LOW | First-mover advantage |
| Kenya | Tier 3 (emerging) | 3–5 days (air) | $0.10–$1/unit | LOW | First-mover advantage |
For suppliers: Tier 1 markets (US, UK, France) require regulatory investment but offer premium pricing. Tier 3 markets (emerging) have low barriers — ideal for first-time exporters. For buyers: Use the price band and lead time to benchmark your current supplier’s terms.
Fig 9.2 0 markets in the Growth Opportunity zone (competitive + growing). 14 in Fragile Dependency (concentrated + shrinking).
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each bubble = one destination. X-axis = HHI (concentration). Y-axis = growth %. Bubble size = USD. Green zone (top-left) = Growth Opportunity — competitive markets that are growing, best for new entrants. Red zone (bottom-right) = Fragile Dependency — concentrated + shrinking, high supply-chain risk. Conclusion: Key markets are the top growth opportunities.
09
PART V — ACTION
Action Plan & Easy-Entry Markets
12 prioritised actions + 15 low-competition destination countries for small & mid-size suppliers
KEY TAKEAWAY
Quick Wins: execute this quarter. Big Bets: plan for next 6–12 months. Plus 15 countries with ≤5 Indian suppliers — the best entry points for SMEs.
S
FOR SUPPLIERS
| ID | Action | Timing | Impact |
|---|---|---|---|
| A1 | Pitch top single-source buyer in United States | This Q | HIGH |
| A2 | Offer alternative to top multi-source buyer | This Q | HIGH |
| A3 | Audit France lock-ins (HHI 10000) | This Q | MED |
| A5 | Enter France (1 suppliers) | This Q | HIGH |
| A6 | Enter Turkmenistan (1 suppliers) | This Q | MED |
| A8 | Build France distribution | 6–12m | HIGH |
| A9 | Bundle injection/infusion catalog for premium markets | 6–12m | MED |
B
FOR BUYERS
| ID | Action | Timing | Impact |
|---|---|---|---|
| A4 | Monitor rising exporters (climbers) | This Q | MED |
| A7 | Register for United States tenders | 6–12m | HIGH |
| A10 | Track quarterly HHI shifts across key destinations | This Q | LOW |
| A11 | Map competitor buyer portfolios quarterly | This Q | MED |
| A12 | Qualify second source for single-source buyers | This Q | MED |
§9.4 Easy-entry markets — 15 countries with ≤5 Indian suppliers
| # | Country | Region | Suppliers | Q4 USD | Growth | Barrier | Why this is easy |
|---|---|---|---|---|---|---|---|
| 1 | France | Other | 1 | $912K | 0% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 2 | Turkmenistan | Asia | 1 | $324K | 0% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 3 | Netherlands | Other | 1 | $182K | 0% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 4 | Barbados | Other | 2 | $8K | 0% | LOW | Only 2 Indian suppliers — near-monopoly, easy second-source entry |
| 5 | Australia | Other | 1 | $4K | 0% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 6 | Venezuela | Other | 1 | $1K | 0% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 7 | United Arab Emirates | Other | 5 | $470 | 0% | LOW | Low competition (5 suppliers), accessible market |
| 8 | New Zealand | Other | 1 | $389 | 0% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 9 | Chad | Africa | 1 | $370 | -100% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 10 | Myanmar | Asia | 1 | $247 | 0% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 11 | Philippines | Asia | 1 | $208 | 0% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 12 | Montserrat | Other | 1 | $114 | 0% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 13 | Kenya | Africa | 1 | $32 | 0% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 14 | Mauritius | Africa | 1 | $15 | 0% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 15 | Somalia | Africa | 1 | $10 | 0% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
This report covers 136 2025-Q4 Verapamil shipments.
TransData Nexus tracks 3.37M+ shipments across all pharmaceuticals since 2020.
→ transdatanexus.com/pharmaceutical/verapamil
10
PART VI — EVIDENCE REGISTER
Comprehensive Shipment Records by Region
Authoritative source behind all analytics in this report — every shipment appears exactly once
KEY TAKEAWAY
This section contains every one of the 136 2025-Q4 verapamil shipments, organised by Region → Exporter → Shipment rows. No row is duplicated.
S FOR SUPPLIERS
Jump to any destination country to see exactly who your competitors ship to, what they charge, through which port, and how often.
B FOR BUYERS
Jump to your country to see every Indian verapamil shipment that arrived in 2025-Q4: supplier, price, dosage, port.
§10.1 Global totals
SHIPMENTS
136
across all regions
TOTAL USD
$4.10M
2025-Q4 FOB value
UNITS
39.9M
tablets, capsules, etc.
SUPPLIERS
30
Indian exporters
BUYERS
26
global importers
COUNTRIES
19
destinations
§10.2 Regional breakdown
§10.3 Key insights from the data
Africa is the largest region at $433.62 (0.0%), spanning 5 countries.
30 Indian suppliers shipped to 26 buyers across 19 countries — average shipment value $30K.
Top 0 markets: .
Every row below is real customs data — date, importer, dosage, brand, quantity, unit price, total USD, origin port, destination port, and transport mode.
§10.4 How to read a country page
1
6 KPI cards — shipments, USD, qty, exporters, importers, avg unit price.
2
4 mini-lists — top exporters, importers, dosages, monthly trend.
3
Shipment register — every row grouped by exporter. No row is duplicated or omitted.
10
PART VI — DRILL-DOWN · AFRICA
Region: Africa
5 countries · 12 shipments · $433.62 · 5 Indian suppliers · 3 buyers
SHIPMENTS
12
USD
$433.62
COUNTRIES
5
SUPPLIERS
5
BUYERS
3
HHI
7,367
concentrated
Top 5 destination countries in Africa
1
Chad (85.4%)
$370.30
2
Kenya (7.3%)
$31.85
3
Mauritius (3.6%)
$15.43
4
Somalia (2.3%)
$10.02
5
Zimbabwe (1.4%)
$6.01
Top 5 Indian suppliers into Africa
1
DROPS PHARMA PVT LTD
$370.30
2
R.S. SURGIPHARM PVT LTD
$31.85
3
SAVA HEALTHCARE LTD
$15.43
4
VEA IMPEX (I) PVT LTD
$10.02
5
RUTVA MEDICARE
$6.01
Top 1 Africa importers
1
REGENCY EXIM TRADE LTD · Mauritius
$15.43
Top 5 dosage forms
1
Tablet
$417.58
2
Unknown
$6.01
3
Solution
$5.01
4
Other
$2.51
5
2ML
$2.51
Monthly trend
| Month | Ships | USD | Avg/ship |
|---|---|---|---|
| Oct | 3 | $376.32 | $125.44 |
| Nov | 1 | $7.66 | $7.66 |
| Dec | 8 | $49.65 | $6.21 |
Shipment register · 12 rows · grouped by exporter
| # | Date | Importer | Country | Dosage | Qty | Unit | Unit $ | Total $ | Origin | Dest | Mode |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SUPPLIER #1 — DROPS PHARMA PVT LTD · 1 shipments · $370.30 | |||||||||||
| 1 | Oct 2025 | UNLISTED BUYER | Chad | Tablet | 1.5K | NOS | $0.247 | $370.30 | COCHIN SEA | N'DJAMENA | AIR |
| SUPPLIER #2 — R.S. SURGIPHARM PVT LTD · 3 shipments · $31.85 | |||||||||||
| 2 | Dec 2025 | UNKNOWN BUYER | Kenya | Tablet | 10 | NOS | $0.271 | $2.71 | MUMBAI AIR (SAHAR) | NAIROBI | AIR |
| 3 | Dec 2025 | UNKNOWN BUYER | Kenya | Tablet | 17 | NOS | $1.60 | $27.20 | MUMBAI AIR (SAHAR) | NAIROBI | AIR |
| 4 | Dec 2025 | UNKNOWN BUYER | Kenya | Tablet | 4 | NOS | $0.485 | $1.94 | MUMBAI AIR (SAHAR) | NAIROBI | AIR |
| SUPPLIER #3 — SAVA HEALTHCARE LTD · 2 shipments · $15.43 | |||||||||||
| 5 | Nov 2025 | REGENCY EXIM TRADE LTD | Mauritius | Tablet | 1 | NOS | $7.66 | $7.66 | MUMBAI AIR (SAHAR) | MAURITIUS | AIR |
| 6 | Dec 2025 | REGENCY EXIM TRADE LTD | Mauritius | Tablet | 1 | NOS | $7.77 | $7.77 | MUMBAI AIR (SAHAR) | MAURITIUS | AIR |
| SUPPLIER #4 — VEA IMPEX (I) PVT LTD · 4 shipments · $10.02 | |||||||||||
| 7 | Dec 2025 | UNLISTED BUYER | Somalia | Other | 1.0K | NOS | $0.0025 | $2.51 | MUMBAI AIR (SAHAR) | HARGEISA | AIR |
| 8 | Dec 2025 | UNLISTED BUYER | Somalia | 2ML | 1.0K | NOS | $0.0025 | $2.51 | MUMBAI AIR (SAHAR) | HARGEISA | AIR |
| 9 | Dec 2025 | UNLISTED BUYER | Somalia | Solution | 1.0K | NOS | $0.0025 | $2.51 | MUMBAI AIR (SAHAR) | HARGEISA | AIR |
| 10 | Dec 2025 | UNLISTED BUYER | Somalia | Solution | 1.0K | NOS | $0.0025 | $2.51 | MUMBAI AIR (SAHAR) | HARGEISA | AIR |
| SUPPLIER #5 — RUTVA MEDICARE · 2 shipments · $6.01 | |||||||||||
| 11 | Oct 2025 | UNLISTED BUYER | Zimbabwe | 10 | PCS | $0.120 | $1.20 | AHMEDABAD AIR | HARARE | AIR | |
| 12 | Oct 2025 | UNLISTED BUYER | Zimbabwe | 40 | PCS | $0.120 | $4.81 | AHMEDABAD AIR | HARARE | AIR | |
10
PART VI — DRILL-DOWN · ASIA
Region: Asia
6 countries · 49 shipments · $451K · 15 Indian suppliers · 11 buyers
SHIPMENTS
49
USD
$451K
COUNTRIES
6
SUPPLIERS
15
BUYERS
11
HHI
5,868
concentrated
Top 6 destination countries in Asia
1
Turkmenistan (71.8%)
$324K
2
Saudi Arabia (27.9%)
$126K
3
United Arab Emirates (0.1%)
$470.24
4
Myanmar (0.1%)
$246.74
5
Philippines (0.0%)
$207.68
6
Maldives (0.0%)
$0.141
Top 15 Indian suppliers into Asia
1
THRIVE THERAPEUTIC PVT LTD
$324K
2
ZYDUS LIFESCIENCES LTD
$120K
3
MYGENIC HEALTHCARE PVT LTD
$5K
4
SONIA LABORATORY PVT LTD
$590.47
5
ALLEGIANCE PHARMA LLP
$387.93
6
DERRIC WOOD
$255.82
7
DECINA PHARMA PVT LTD
$246.74
8
WELCURE REMEDIES
$207.68
9
DROPS PHARMA PVT LTD
$133.40
10
ZYPHARS PHARMACEUTICS PVT LTD
$55.92
11
MEDEX PHARMACEUTICALS
$16.24
12
CLOVERLEAF ECOM PVT LTD
$8.86
13
RMPL PHARMA LLP
$7.05
14
BARAKAH BIOHEALTH LLP
$3.99
15
HEMS ( INDIA )
$0.141
Top 9 Asia importers
1
QOMEL COMPANY · Saudi Arabia
$120K
2
AL MAAYER ALASRYAH COMPANY · Saudi Arabia
$590.47
3
TO THE CONSIGNEE · United Arab Emirates
$443.85
4
EMIRATES POST COMPANY · United Arab Emirates
$255.82
5
IMPERIAL PHOENIX CO LTD · Myanmar
$246.74
6
CM STAR CORP · Philippines
$207.68
7
MEDISUITE MEDICAL STORE · United Arab Emirates
$12.25
8
EMIRATES POST GROUP · United Arab Emirates
$8.86
9
BEST INTERNATIONAL FZE · United Arab Emirates
$4.00
Top 4 dosage forms
1
Tablet
$324K
2
Injection
$127K
3
SR
$45.92
4
Unknown
$2.62
Monthly trend
| Month | Ships | USD | Avg/ship |
|---|---|---|---|
| Oct | 0 | $0.0000 | — |
| Nov | 20 | $1K | $62.42 |
| Dec | 29 | $449K | $15K |
Shipment register · 49 rows · grouped by exporter
| # | Date | Importer | Country | Dosage | Qty | Unit | Unit $ | Total $ | Origin | Dest | Mode |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SUPPLIER #1 — THRIVE THERAPEUTIC PVT LTD · 2 shipments · $324K | |||||||||||
| 1 | Dec 2025 | UNLISTED BUYER | Turkmenistan | Tablet | 10.0K | NOS | $16.19 | $162K | DELHI AIR | AIR | |
| 2 | Dec 2025 | UNLISTED BUYER | Turkmenistan | Tablet | 10.0K | NOS | $16.18 | $162K | DELHI AIR | ASHKHABAD | AIR |
| SUPPLIER #2 — ZYDUS LIFESCIENCES LTD · 1 shipments · $120K | |||||||||||
| 3 | Dec 2025 | QOMEL COMPANY | Saudi Arabia | Injection | 39.1K | NOS | $3.06 | $120K | AHMEDABAD AIR | RIYADH | AIR |
| SUPPLIER #3 — MYGENIC HEALTHCARE PVT LTD · 2 shipments · $5K | |||||||||||
| 4 | Nov 2025 | UNKNOWN BUYER | Saudi Arabia | Injection | 1.4K | NOS | $0.499 | $699.20 | MUMBAI AIR (SAHAR) | JEDDAH | AIR |
| 5 | Dec 2025 | UNKNOWN BUYER | Saudi Arabia | Injection | 4.6K | NOS | $1.00 | $5K | MUMBAI AIR (SAHAR) | JEDDAH | AIR |
| SUPPLIER #4 — SONIA LABORATORY PVT LTD · 1 shipments · $590.47 | |||||||||||
| 6 | Dec 2025 | AL MAAYER ALASRYAH COMPANY | Saudi Arabia | Injection | 3.0K | NOS | $0.197 | $590.47 | MUMBAI AIR (SAHAR) | JEDDAH | AIR |
| SUPPLIER #5 — ALLEGIANCE PHARMA LLP · 2 shipments · $387.93 | |||||||||||
| 7 | Dec 2025 | TO THE CONSIGNEE | Saudi Arabia | Injection | 100 | NOS | $1.94 | $193.97 | MUMBAI AIR (SAHAR) | JEDDAH | AIR |
| 8 | Dec 2025 | TO THE CONSIGNEE | Saudi Arabia | Injection | 100 | NOS | $1.94 | $193.97 | MUMBAI AIR (SAHAR) | JEDDAH | AIR |
| SUPPLIER #6 — DERRIC WOOD · 27 shipments · $255.82 | |||||||||||
| 9 | Nov 2025 | EMIRATES POST COMPANY | United Arab Emirates | Tablet | 6 | PCS | $0.956 | $5.74 | DELHI AIR | DUBAI | AIR |
| 10 | Nov 2025 | EMIRATES POST COMPANY | United Arab Emirates | Tablet | 6 | PCS | $1.91 | $11.48 | DELHI AIR | DUBAI | AIR |
| 11 | Nov 2025 | EMIRATES POST COMPANY | United Arab Emirates | Tablet | 6 | PCS | $0.956 | $5.74 | DELHI AIR | DUBAI | AIR |
| 12 | Nov 2025 | EMIRATES POST COMPANY | United Arab Emirates | Tablet | 6 | PCS | $1.91 | $11.48 | DELHI AIR | DUBAI | AIR |
| 13 | Nov 2025 | EMIRATES POST COMPANY | United Arab Emirates | Tablet | 6 | PCS | $0.961 | $5.76 | DELHI AIR | DUBAI | AIR |
| 14 | Nov 2025 | EMIRATES POST COMPANY | United Arab Emirates | SR | 24 | PCS | $0.959 | $23.03 | DELHI AIR | DUBAI | AIR |
| 15 | Nov 2025 | EMIRATES POST COMPANY | United Arab Emirates | SR | 12 | PCS | $1.91 | $22.89 | DELHI AIR | DUBAI | AIR |
| 16 | Nov 2025 | EMIRATES POST COMPANY | United Arab Emirates | Tablet | 1 | PCS | $0.313 | $0.313 | DELHI AIR | DUBAI | AIR |
| 17 | Nov 2025 | EMIRATES POST COMPANY | United Arab Emirates | Tablet | 6 | PCS | $0.558 | $3.35 | DELHI AIR | DUBAI | AIR |
| 18 | Nov 2025 | EMIRATES POST COMPANY | United Arab Emirates | Tablet | 12 | PCS | $0.959 | $11.51 | DELHI AIR | DUBAI | AIR |
| 19 | Nov 2025 | EMIRATES POST COMPANY | United Arab Emirates | Tablet | 12 | PCS | $1.91 | $22.89 | DELHI AIR | DUBAI | AIR |
| 20 | Nov 2025 | EMIRATES POST COMPANY | United Arab Emirates | Tablet | 1 | PCS | $0.315 | $0.315 | DELHI AIR | DUBAI | AIR |
| 21 | Nov 2025 | EMIRATES POST COMPANY | United Arab Emirates | Tablet | 6 | PCS | $0.561 | $3.37 | DELHI AIR | DUBAI | AIR |
| 22 | Nov 2025 | EMIRATES POST COMPANY | United Arab Emirates | Tablet | 12 | PCS | $0.966 | $11.59 | DELHI AIR | DUBAI | AIR |
| 23 | Nov 2025 | EMIRATES POST COMPANY | United Arab Emirates | Tablet | 12 | PCS | $1.92 | $23.05 | DELHI AIR | DUBAI | AIR |
| 24 | Dec 2025 | EMIRATES POST COMPANY | United Arab Emirates | Tablet | 12 | PCS | $1.92 | $23.00 | DELHI AIR | DUBAI | AIR |
| 25 | Dec 2025 | EMIRATES POST COMPANY | United Arab Emirates | Tablet | 12 | PCS | $1.97 | $23.63 | DELHI AIR | DUBAI | AIR |
| 26 | Dec 2025 | EMIRATES POST COMPANY | United Arab Emirates | Tablet | 6 | PCS | $1.91 | $11.48 | DELHI AIR | DUBAI | AIR |
| 27 | Dec 2025 | EMIRATES POST COMPANY | United Arab Emirates | Tablet | 6 | PCS | $0.0000 | $0.0000 | DELHI AIR | DUBAI | AIR |
| 28 | Dec 2025 | EMIRATES POST COMPANY | United Arab Emirates | Tablet | 12 | PCS | $0.0000 | $0.0000 | DELHI AIR | DUBAI | AIR |
| 29 | Dec 2025 | EMIRATES POST COMPANY | United Arab Emirates | Tablet | 24 | PCS | $0.0000 | $0.0000 | DELHI AIR | DUBAI | AIR |
| 30 | Dec 2025 | EMIRATES POST COMPANY | United Arab Emirates | Tablet | 6 | PCS | $0.0055 | $0.033 | DELHI AIR | DUBAI | AIR |
| 31 | Dec 2025 | EMIRATES POST COMPANY | United Arab Emirates | Tablet | 12 | PCS | $0.0092 | $0.111 | DELHI AIR | DUBAI | AIR |
| 32 | Dec 2025 | EMIRATES POST COMPANY | United Arab Emirates | Tablet | 24 | PCS | $0.018 | $0.444 | DELHI AIR | DUBAI | AIR |
| 33 | Dec 2025 | EMIRATES POST COMPANY | United Arab Emirates | Tablet | 6 | PCS | $0.0092 | $0.055 | DELHI AIR | DUBAI | AIR |
| 34 | Dec 2025 | EMIRATES POST COMPANY | United Arab Emirates | Tablet | 12 | PCS | $0.961 | $11.53 | DELHI AIR | DUBAI | AIR |
| 35 | Dec 2025 | EMIRATES POST COMPANY | United Arab Emirates | Tablet | 12 | PCS | $1.92 | $23.06 | DELHI AIR | DUBAI | AIR |
| SUPPLIER #7 — DECINA PHARMA PVT LTD · 1 shipments · $246.74 | |||||||||||
| 36 | Nov 2025 | IMPERIAL PHOENIX CO LTD | Myanmar | Injection | 1.5K | NOS | $0.164 | $246.74 | NHAVA SHEVA SEA (JNPT) | Yangon | SEA |
| SUPPLIER #8 — WELCURE REMEDIES · 1 shipments · $207.68 | |||||||||||
| 37 | Dec 2025 | CM STAR CORP | Philippines | Injection | 775 | NOS | $0.268 | $207.68 | DELHI AIR | MANILA | AIR |
| SUPPLIER #9 — DROPS PHARMA PVT LTD · 1 shipments · $133.40 | |||||||||||
| 38 | Nov 2025 | UNLISTED BUYER | United Arab Emirates | Injection | 30 | NOS | $4.45 | $133.40 | COCHIN AIR | DUBAI | AIR |
| SUPPLIER #10 — ZYPHARS PHARMACEUTICS PVT LTD · 3 shipments · $55.92 | |||||||||||
| 39 | Dec 2025 | TO THE CONSIGNEE | United Arab Emirates | Injection | 10 | NOS | $3.12 | $31.24 | MUMBAI AIR (SAHAR) | DUBAI | AIR |
| 40 | Dec 2025 | TO THE CONSIGNEE | United Arab Emirates | Injection | 5 | NOS | $2.55 | $12.75 | MUMBAI AIR (SAHAR) | DUBAI | AIR |
| 41 | Dec 2025 | TO THE CONSIGNEE | United Arab Emirates | Injection | 5 | NOS | $2.39 | $11.93 | MUMBAI AIR (SAHAR) | DUBAI | AIR |
| SUPPLIER #11 — MEDEX PHARMACEUTICALS · 2 shipments · $16.24 | |||||||||||
| 42 | Nov 2025 | BEST INTERNATIONAL FZE | United Arab Emirates | Injection | 20 | NOS | $0.200 | $4.00 | MUMBAI AIR (SAHAR) | DUBAI | AIR |
| 43 | Dec 2025 | MEDISUITE MEDICAL STORE | United Arab Emirates | Injection | 50 | NOS | $0.245 | $12.25 | MUMBAI AIR (SAHAR) | DUBAI | AIR |
| SUPPLIER #12 — CLOVERLEAF ECOM PVT LTD · 2 shipments · $8.86 | |||||||||||
| 44 | Nov 2025 | EMIRATES POST GROUP | United Arab Emirates | 5 | NOS | $0.525 | $2.62 | MUMBAI AIR (SAHAR) | DUBAI | AIR | |
| 45 | Dec 2025 | EMIRATES POST GROUP | United Arab Emirates | Tablet | 12 | NOS | $0.520 | $6.24 | MUMBAI AIR (SAHAR) | DUBAI | AIR |
| SUPPLIER #13 — RMPL PHARMA LLP · 1 shipments · $7.05 | |||||||||||
| 46 | Dec 2025 | UNLISTED BUYER | Saudi Arabia | Injection | 4.2K | PCS | $0.0017 | $7.05 | MUMBAI AIR (SAHAR) | JEDDAH | SEA |
| SUPPLIER #14 — BARAKAH BIOHEALTH LLP · 2 shipments · $3.99 | |||||||||||
| 47 | Dec 2025 | UNLISTED BUYER | Saudi Arabia | Injection | 2.0K | NOS | $0.0000 | $0.0000 | CHENNAI AIR | JEDDAH | AIR |
| 48 | Dec 2025 | UNLISTED BUYER | Saudi Arabia | Injection | 2.0K | NOS | $0.0020 | $3.99 | CHENNAI AIR | JEDDAH | AIR |
| SUPPLIER #15 — HEMS ( INDIA ) · 1 shipments · $0.141 | |||||||||||
| 49 | Dec 2025 | UNLISTED BUYER | Maldives | Tablet | 90 | NOS | $0.0016 | $0.141 | CHENNAI AIR | MALE | AIR |
10
PART VI — DRILL-DOWN · EUROPE
Region: Europe
2 countries · 12 shipments · $1.09M · 1 Indian suppliers · 2 buyers
SHIPMENTS
12
USD
$1.09M
COUNTRIES
2
SUPPLIERS
1
BUYERS
2
HHI
10,000
concentrated
Top 2 destination countries in Europe
1
France (83.3%)
$912K
2
Netherlands (16.7%)
$182K
Top 1 Indian suppliers into Europe
1
MYLAN LABORATORIES LTD
$1.09M
Top 1 Europe importers
1
BGP PRODUCTS GMBH · Netherlands
$182K
Top 2 dosage forms
1
Tablet
$912K
2
Unknown
$182K
Monthly trend
| Month | Ships | USD | Avg/ship |
|---|---|---|---|
| Oct | 0 | $0.0000 | — |
| Nov | 10 | $910K | $91K |
| Dec | 2 | $184K | $92K |
Shipment register · 12 rows · grouped by exporter
| # | Date | Importer | Country | Dosage | Qty | Unit | Unit $ | Total $ | Origin | Dest | Mode |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SUPPLIER #1 — MYLAN LABORATORIES LTD · 12 shipments · $1.09M | |||||||||||
| 1 | Nov 2025 | BGP PRODUCTS GMBH | Netherlands | Tablet | 1.2M | NOS | $0.075 | $91K | MUMBAI AIR (SAHAR) | AMSTERDAM, SCHIPHOL | AIR |
| 2 | Nov 2025 | BGP PRODUCTS GMBH | Netherlands | Tablet | 1.2M | NOS | $0.075 | $91K | MUMBAI AIR (SAHAR) | AMSTERDAM, SCHIPHOL | AIR |
| 3 | Nov 2025 | UNKNOWN BUYER | France | 1.2M | NOS | $0.076 | $91K | MUMBAI AIR (SAHAR) | LYON | AIR | |
| 4 | Nov 2025 | UNKNOWN BUYER | France | 1.2M | NOS | $0.076 | $91K | MUMBAI AIR (SAHAR) | LYON | AIR | |
| 5 | Nov 2025 | UNKNOWN BUYER | France | Tablet | 1.2M | NOS | $0.076 | $91K | MUMBAI AIR (SAHAR) | LYON | AIR |
| 6 | Nov 2025 | UNKNOWN BUYER | France | Tablet | 1.2M | NOS | $0.076 | $91K | MUMBAI AIR (SAHAR) | LYON | AIR |
| 7 | Nov 2025 | UNKNOWN BUYER | France | Tablet | 1.2M | NOS | $0.076 | $91K | MUMBAI AIR (SAHAR) | LYON | AIR |
| 8 | Nov 2025 | UNKNOWN BUYER | France | Tablet | 1.2M | NOS | $0.076 | $91K | MUMBAI AIR (SAHAR) | LYON | AIR |
| 9 | Nov 2025 | UNKNOWN BUYER | France | Tablet | 1.2M | NOS | $0.076 | $91K | MUMBAI AIR (SAHAR) | LYON | AIR |
| 10 | Nov 2025 | UNKNOWN BUYER | France | Tablet | 1.2M | NOS | $0.076 | $91K | MUMBAI AIR (SAHAR) | LYON | AIR |
| 11 | Dec 2025 | UNKNOWN BUYER | France | Tablet | 1.2M | NOS | $0.077 | $91K | MUMBAI AIR (SAHAR) | LYON | AIR |
| 12 | Dec 2025 | UNKNOWN BUYER | France | Tablet | 1.2M | NOS | $0.078 | $93K | MUMBAI AIR (SAHAR) | LYON | AIR |
10
PART VI — DRILL-DOWN · AMERICAS
Region: Americas
4 countries · 58 shipments · $2.55M · 12 Indian suppliers · 13 buyers
SHIPMENTS
58
USD
$2.55M
COUNTRIES
4
SUPPLIERS
12
BUYERS
13
HHI
2,787
concentrated
Top 4 destination countries in Americas
1
United States (99.7%)
$2.54M
2
Barbados (0.3%)
$8K
3
Venezuela (0.0%)
$1K
4
Montserrat (0.0%)
$113.67
Top 12 Indian suppliers into Americas
1
GLENMARK PHARMACEUTICALS LTD
$1.02M
2
MYLAN LABORATORIES LTD
$687K
3
CADILA PHARMACEUTICALS LTD
$528K
4
ZYDUS LIFESCIENCES LTD
$126K
5
MANKIND PHARMA LTD
$70K
6
SOMERSET THERAPEUTICS PVT LTD
$59K
7
STERIL-GENE LIFE SCIENCES PVT LTD
$51K
8
MCARE IMPEX PVT LTD
$7K
9
WATSON PHARMA PVT LTD
$2K
10
KWALITY PHARMACEUTICALS LTD
$1K
11
DRIVECURE HEALTHCARE PVT LTD
$605.22
12
SUNNY PHARMA
$113.67
Top 11 Americas importers
1
GLENMARK PHARMACEUTICALS INC · United States
$983K
2
MYLAN PHARMACEUTICALS INC · United States
$687K
3
LIFESCIENCE LOGISTICS · United States
$528K
4
EVERSANA LIFE SCIENCE SERVICES LLC · United States
$126K
5
LIFESTAR PHARMA LLC · United States
$70K
6
RX CROSSROADS 3PL LLC · United States
$52K
7
AVET PHARMACEUTICALS INC · United States
$51K
8
ACTAVIS LLC · United States
$2K
9
LABORATORIOS REMENY, C.A · Venezuela
$1K
10
TO THE INVOICE RAISED TO MANGER OF · Barbados
$605.22
11
CENTRAL MEDICAL STORES, MINISTRY OF · Montserrat
$113.67
Top 5 dosage forms
1
Tablet
$1.53M
2
Capsule
$687K
3
Injection
$306K
4
Unknown
$28K
5
prolonged release tablets
$2K
Monthly trend
| Month | Ships | USD | Avg/ship |
|---|---|---|---|
| Oct | 5 | $347K | $69K |
| Nov | 20 | $809K | $40K |
| Dec | 33 | $1.39M | $42K |
Shipment register · 58 rows · grouped by exporter
| # | Date | Importer | Country | Dosage | Qty | Unit | Unit $ | Total $ | Origin | Dest | Mode |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SUPPLIER #1 — GLENMARK PHARMACEUTICALS LTD · 20 shipments · $1.02M | |||||||||||
| 1 | Oct 2025 | GLENMARK PHARMACEUTICALS INC | United States | Tablet | 5.0K | NOS | $12.67 | $64K | NHAVA SHEVA SEA (JNPT) | New York | SEA |
| 2 | Oct 2025 | GLENMARK PHARMACEUTICALS INC | United States | Tablet | 5.0K | NOS | $12.67 | $64K | NHAVA SHEVA SEA (JNPT) | New York | SEA |
| 3 | Oct 2025 | GLENMARK PHARMACEUTICALS INC | United States | Tablet | 4.1K | NOS | $17.73 | $73K | NHAVA SHEVA SEA (JNPT) | New York | SEA |
| 4 | Oct 2025 | GLENMARK PHARMACEUTICALS INC | United States | Tablet | 6.2K | NOS | $17.81 | $110K | NHAVA SHEVA SEA (JNPT) | New York | SEA |
| 5 | Oct 2025 | GLENMARK PHARMACEUTICALS INC | United States | Tablet | 2.1K | NOS | $17.59 | $36K | NHAVA SHEVA SEA (JNPT) | New York | SEA |
| 6 | Nov 2025 | GLENMARK PHARMACEUTICALS INC | United States | Tablet | 13.8K | NOS | $1.87 | $26K | NHAVA SHEVA SEA (JNPT) | Newark Apt/New York | SEA |
| 7 | Nov 2025 | GLENMARK PHARMACEUTICALS INC | United States | Tablet | 7.1K | NOS | $1.86 | $13K | NHAVA SHEVA SEA (JNPT) | Newark Apt/New York | SEA |
| 8 | Nov 2025 | GLENMARK PHARMACEUTICALS INC | United States | Tablet | 41.8K | NOS | $1.86 | $78K | NHAVA SHEVA SEA (JNPT) | Newark Apt/New York | SEA |
| 9 | Nov 2025 | GLENMARK PHARMACEUTICALS INC | United States | Tablet | 10.4K | NOS | $3.17 | $33K | MUMBAI AIR (SAHAR) | NEW YORK | AIR |
| 10 | Nov 2025 | UNKNOWN BUYER | United States | Tablet | 10.4K | NOS | $3.17 | $33K | MUMBAI AIR (SAHAR) | NEW YORK | AIR |
| 11 | Nov 2025 | GLENMARK PHARMACEUTICALS INC | United States | Tablet | 9.3K | NOS | $2.75 | $26K | NHAVA SHEVA SEA (JNPT) | Newark Apt/New York | SEA |
| 12 | Nov 2025 | GLENMARK PHARMACEUTICALS INC | United States | Tablet | 7.1K | NOS | $2.73 | $19K | NHAVA SHEVA SEA (JNPT) | New York | SEA |
| 13 | Nov 2025 | GLENMARK PHARMACEUTICALS INC | United States | Tablet | 4.6K | NOS | $2.41 | $11K | MUMBAI AIR (SAHAR) | NEW YORK | AIR |
| 14 | Dec 2025 | GLENMARK PHARMACEUTICALS INC | United States | Tablet | 6.5K | NOS | $2.77 | $18K | NHAVA SHEVA SEA (JNPT) | New York | SEA |
| 15 | Dec 2025 | GLENMARK PHARMACEUTICALS INC | United States | Tablet | 5.0K | NOS | $14.66 | $73K | MUMBAI AIR (SAHAR) | NEW YORK | AIR |
| 16 | Dec 2025 | GLENMARK PHARMACEUTICALS INC | United States | Tablet | 1.2K | NOS | $13.17 | $16K | MUMBAI AIR (SAHAR) | NEW YORK | AIR |
| 17 | Dec 2025 | GLENMARK PHARMACEUTICALS INC | United States | Tablet | 10.0K | NOS | $15.25 | $153K | NHAVA SHEVA SEA (JNPT) | New York | SEA |
| 18 | Dec 2025 | GLENMARK PHARMACEUTICALS INC | United States | Tablet | 2.4K | NOS | $13.70 | $33K | NHAVA SHEVA SEA (JNPT) | New York | SEA |
| 19 | Dec 2025 | GLENMARK PHARMACEUTICALS INC | United States | Tablet | 1.3K | NOS | $13.07 | $17K | NHAVA SHEVA SEA (JNPT) | New York | SEA |
| 20 | Dec 2025 | GLENMARK PHARMACEUTICALS INC | United States | Tablet | 62.7K | NOS | $1.92 | $120K | NHAVA SHEVA SEA (JNPT) | Newark Apt/New York | SEA |
| SUPPLIER #2 — MYLAN LABORATORIES LTD · 7 shipments · $687K | |||||||||||
| 21 | Nov 2025 | MYLAN PHARMACEUTICALS INC | United States | Capsule | 1.9M | NOS | $0.061 | $115K | MUMBAI AIR (SAHAR) | ATLANTA, HARTSFIELD | AIR |
| 22 | Nov 2025 | MYLAN PHARMACEUTICALS INC | United States | Capsule | 1.0M | NOS | $0.090 | $91K | MUMBAI AIR (SAHAR) | ATLANTA, HARTSFIELD | AIR |
| 23 | Nov 2025 | MYLAN PHARMACEUTICALS INC | United States | Capsule | 947.2K | NOS | $0.107 | $102K | MUMBAI AIR (SAHAR) | ATLANTA, HARTSFIELD | AIR |
| 24 | Dec 2025 | MYLAN PHARMACEUTICALS INC | United States | Capsule | 1.6M | NOS | $0.086 | $139K | NHAVA SHEVA SEA (JNPT) | Norfolk | SEA |
| 25 | Dec 2025 | MYLAN PHARMACEUTICALS INC | United States | Capsule | 961.2K | NOS | $0.110 | $105K | MUMBAI AIR (SAHAR) | ATLANTA, HARTSFIELD | AIR |
| 26 | Dec 2025 | MYLAN PHARMACEUTICALS INC | United States | Capsule | 946.8K | NOS | $0.110 | $104K | MUMBAI AIR (SAHAR) | ATLANTA, HARTSFIELD | AIR |
| 27 | Dec 2025 | MYLAN PHARMACEUTICALS INC | United States | Capsule | 339.4K | NOS | $0.092 | $31K | MUMBAI AIR (SAHAR) | ATLANTA, HARTSFIELD | AIR |
| SUPPLIER #3 — CADILA PHARMACEUTICALS LTD · 5 shipments · $528K | |||||||||||
| 28 | Nov 2025 | LIFESCIENCE LOGISTICS | United States | 854.4K | TBS | $0.033 | $28K | AHMEDABAD AIR | CHICAGO, IL | AIR | |
| 29 | Nov 2025 | LIFESCIENCE LOGISTICS | United States | Tablet | 3.1M | TBS | $0.041 | $128K | AHMEDABAD AIR | CHICAGO, IL | AIR |
| 30 | Dec 2025 | LIFESCIENCE LOGISTICS | United States | Tablet | 3.4M | TBS | $0.034 | $116K | AHMEDABAD AIR | WASHINGTON, DULLES I | AIR |
| 31 | Dec 2025 | LIFESCIENCE LOGISTICS | United States | Tablet | 2.3M | TBS | $0.055 | $127K | AHMEDABAD AIR | WASHINGTON, DULLES I | AIR |
| 32 | Dec 2025 | LIFESCIENCE LOGISTICS | United States | Tablet | 3.1M | TBS | $0.043 | $130K | AHMEDABAD AIR | CHICAGO, IL | AIR |
| SUPPLIER #4 — ZYDUS LIFESCIENCES LTD · 1 shipments · $126K | |||||||||||
| 33 | Dec 2025 | EVERSANA LIFE SCIENCE SERVICES LLC | United States | Injection | 79.0K | VLS | $1.60 | $126K | MUMBAI AIR (SAHAR) | MEMPHIS, TN | AIR |
| SUPPLIER #5 — MANKIND PHARMA LTD · 3 shipments · $70K | |||||||||||
| 34 | Nov 2025 | LIFESTAR PHARMA LLC | United States | Injection | 1.3K | NOS | $29.44 | $37K | DELHI AIR | NEW YORK - JOHN F. K | AIR |
| 35 | Nov 2025 | LIFESTAR PHARMA LLC | United States | Injection | 1.9K | NOS | $5.75 | $11K | DELHI AIR | NEW YORK - JOHN F. K | AIR |
| 36 | Dec 2025 | LIFESTAR PHARMA LLC | United States | Injection | 2.0K | NOS | $11.10 | $22K | DELHI AIR | CHICAGO O'HARE INT'L | AIR |
| SUPPLIER #6 — SOMERSET THERAPEUTICS PVT LTD · 4 shipments · $59K | |||||||||||
| 37 | Nov 2025 | RX CROSSROADS 3PL LLC | United States | Injection | 1.9K | NOS | $2.72 | $5K | BANGALORE ICD | Norfolk | ICD |
| 38 | Nov 2025 | RX CROSSROADS 3PL LLC | United States | Injection | 2.9K | NOS | $13.61 | $39K | BANGALORE ICD | Norfolk | ICD |
| 39 | Nov 2025 | RX CROSSROADS 3PL LLC | United States | Injection | 540 | NOS | $13.73 | $7K | BANGALORE AIR | MATTHEWS RIDG | AIR |
| 40 | Nov 2025 | UNKNOWN BUYER | United States | Injection | 540 | NOS | $13.73 | $7K | BANGALORE AIR | MATTHEWS RIDG | AIR |
| SUPPLIER #7 — STERIL-GENE LIFE SCIENCES PVT LTD · 1 shipments · $51K | |||||||||||
| 41 | Dec 2025 | AVET PHARMACEUTICALS INC | United States | Injection | 6.1K | VLS | $8.30 | $51K | CHENNAI AIR | CHICAGO O'HARE INT'L | AIR |
| SUPPLIER #8 — MCARE IMPEX PVT LTD · 12 shipments · $7K | |||||||||||
| 42 | Dec 2025 | UNLISTED BUYER | Barbados | Tablet | 18 | PCS | $17.30 | $311.35 | DELHI AIR | BRIDGETOWN | AIR |
| 43 | Dec 2025 | UNLISTED BUYER | Barbados | Tablet | 65 | PCS | $17.30 | $1K | DELHI AIR | BRIDGETOWN | AIR |
| 44 | Dec 2025 | UNLISTED BUYER | Barbados | Tablet | 17 | PCS | $17.30 | $294.06 | DELHI AIR | BRIDGETOWN | AIR |
| 45 | Dec 2025 | UNLISTED BUYER | Barbados | prolonged release tablets | 18 | PCS | $17.30 | $311.35 | DELHI AIR | BRIDGETOWN | AIR |
| 46 | Dec 2025 | UNLISTED BUYER | Barbados | prolonged release tablets | 65 | PCS | $17.30 | $1K | DELHI AIR | BRIDGETOWN | AIR |
| 47 | Dec 2025 | UNLISTED BUYER | Barbados | prolonged release tablets | 17 | PCS | $17.30 | $294.06 | DELHI AIR | BRIDGETOWN | AIR |
| 48 | Dec 2025 | UNLISTED BUYER | Barbados | Tablet | 18 | PCS | $17.30 | $311.35 | DELHI AIR | BRIDGETOWN | AIR |
| 49 | Dec 2025 | UNLISTED BUYER | Barbados | Tablet | 65 | PCS | $17.30 | $1K | DELHI AIR | BRIDGETOWN | AIR |
| 50 | Dec 2025 | UNLISTED BUYER | Barbados | Tablet | 17 | PCS | $17.30 | $294.06 | DELHI AIR | BRIDGETOWN | AIR |
| 51 | Dec 2025 | UNLISTED BUYER | Barbados | Tablet | 18 | PCS | $17.30 | $311.35 | DELHI AIR | BRIDGETOWN | AIR |
| 52 | Dec 2025 | UNLISTED BUYER | Barbados | Tablet | 65 | PCS | $17.30 | $1K | DELHI AIR | BRIDGETOWN | AIR |
| 53 | Dec 2025 | UNLISTED BUYER | Barbados | Tablet | 17 | PCS | $17.30 | $294.06 | DELHI AIR | BRIDGETOWN | AIR |
| SUPPLIER #9 — WATSON PHARMA PVT LTD · 2 shipments · $2K | |||||||||||
| 54 | Dec 2025 | ACTAVIS LLC | United States | Tablet | 871 | KGS | $1.28 | $1K | MUMBAI AIR (SAHAR) | NEW YORK - JOHN F. K | AIR |
| 55 | Dec 2025 | ACTAVIS LLC | United States | Tablet | 883 | KGS | $1.28 | $1K | MUMBAI AIR (SAHAR) | NEW YORK - JOHN F. K | AIR |
| SUPPLIER #10 — KWALITY PHARMACEUTICALS LTD · 1 shipments · $1K | |||||||||||
| 56 | Nov 2025 | LABORATORIOS REMENY, C.A | Venezuela | Tablet | 36.0K | NOS | $0.034 | $1K | DELHI AIR | CARACAS | AIR |
| SUPPLIER #11 — DRIVECURE HEALTHCARE PVT LTD · 1 shipments · $605.22 | |||||||||||
| 57 | Dec 2025 | TO THE INVOICE RAISED TO MANGER OF | Barbados | Tablet | 80 | NOS | $7.57 | $605.22 | MUMBAI AIR (SAHAR) | BRIDGETOWN | AIR |
| SUPPLIER #12 — SUNNY PHARMA · 1 shipments · $113.67 | |||||||||||
| 58 | Dec 2025 | CENTRAL MEDICAL STORES, MINISTRY OF | Montserrat | Tablet | 5 | NOS | $22.73 | $113.67 | MUMBAI AIR (SAHAR) | MONTSERRAT | AIR |
10
PART VI — DRILL-DOWN · OCEANIA
Region: Oceania
2 countries · 5 shipments · $4K · 1 Indian suppliers · 2 buyers
SHIPMENTS
5
USD
$4K
COUNTRIES
2
SUPPLIERS
1
BUYERS
2
HHI
10,000
concentrated
Top 2 destination countries in Oceania
1
Australia (90.3%)
$4K
2
New Zealand (9.7%)
$389.19
Top 1 Indian suppliers into Oceania
1
MYLAN LABORATORIES LTD
$4K
Top 2 Oceania importers
1
VIATRIS PTY LTD · Australia
$4K
2
VIATRIS LTD · New Zealand
$389.19
Top 1 dosage forms
1
Tablet
$4K
Monthly trend
| Month | Ships | USD | Avg/ship |
|---|---|---|---|
| Oct | 0 | $0.0000 | — |
| Nov | 0 | $0.0000 | — |
| Dec | 5 | $4K | $802.37 |
Shipment register · 5 rows · grouped by exporter
| # | Date | Importer | Country | Dosage | Qty | Unit | Unit $ | Total $ | Origin | Dest | Mode |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SUPPLIER #1 — MYLAN LABORATORIES LTD · 5 shipments · $4K | |||||||||||
| 1 | Dec 2025 | VIATRIS LTD | New Zealand | Tablet | 453.6K | NOS | $0.0009 | $389.19 | MUMBAI AIR (SAHAR) | AUCKLAND | AIR |
| 2 | Dec 2025 | VIATRIS PTY LTD | Australia | Tablet | 639.9K | NOS | $0.0009 | $549.04 | MUMBAI AIR (SAHAR) | BRISBANE | AIR |
| 3 | Dec 2025 | VIATRIS PTY LTD | Australia | Tablet | 1.2M | NOS | $0.0009 | $1K | MUMBAI AIR (SAHAR) | BRISBANE | SEA |
| 4 | Dec 2025 | VIATRIS PTY LTD | Australia | Tablet | 1.2M | NOS | $0.0009 | $1K | MUMBAI AIR (SAHAR) | BRISBANE | AIR |
| 5 | Dec 2025 | VIATRIS PTY LTD | Australia | Tablet | 1.2M | NOS | $0.0009 | $1K | MUMBAI AIR (SAHAR) | BRISBANE | SEA |
10
PART VI — EVIDENCE REGISTER
Indian Supplier Directory
All 30 Indian verapamil exporters — complete list ranked by USD
KEY TAKEAWAY
This directory lists every Indian company that shipped verapamil in 2025-Q4.
S FOR SUPPLIERS
Find yourself and your competitors. Compare shipment count, USD, and destination regions.
B FOR BUYERS
Search for potential Indian suppliers. Filter by dosage form and destination region.
| # | Supplier | City | Ships | USD | Dosage forms | Primary regions |
|---|---|---|---|---|---|---|
| 1 | MYLAN LABORATORIES LTD | AURANGABAD | 24 | $1.79M | Tablet, Capsule | Europe, Americas |
| 2 | GLENMARK PHARMACEUTICALS LTD | MUMBAI. MAHARASHTRA | 20 | $1.02M | Tablet | Americas |
| 3 | CADILA PHARMACEUTICALS LTD | AHMEDABAD | 5 | $528K | Tablet | Americas |
| 4 | THRIVE THERAPEUTIC PVT LTD | THANE | 2 | $324K | Tablet | Asia |
| 5 | ZYDUS LIFESCIENCES LTD | AHMEDABAD | 2 | $246K | Injection | Americas, Asia |
| 6 | MANKIND PHARMA LTD | HIMANCHAL PRADESH | 3 | $70K | Injection | Americas |
| 7 | SOMERSET THERAPEUTICS PVT LTD | BENGALURU | 4 | $59K | Injection | Americas |
| 8 | STERIL-GENE LIFE SCIENCES PVT LTD | VILLIANUR COMMUNE PONDY | 1 | $51K | Injection | Americas |
| 9 | MCARE IMPEX PVT LTD | ALIGARH | 12 | $7K | Tablet, prolonged release tablets | Americas |
| 10 | MYGENIC HEALTHCARE PVT LTD | NAVI MUMBAI | 2 | $5K | Injection | Asia |
| 11 | WATSON PHARMA PVT LTD | GOA | 2 | $2K | Tablet | Americas |
| 12 | KWALITY PHARMACEUTICALS LTD | AMRITSAR | 1 | $1K | Tablet | Americas |
| 13 | DRIVECURE HEALTHCARE PVT LTD | PUNE | 1 | $605.22 | Tablet | Americas |
| 14 | SONIA LABORATORY PVT LTD | VADODARA | 1 | $590.47 | Injection | Asia |
| 15 | DROPS PHARMA PVT LTD | HOSDURG | 2 | $503.70 | Tablet, Injection | Africa, Asia |
| 16 | ALLEGIANCE PHARMA LLP | PUNE | 2 | $387.93 | Injection | Asia |
| 17 | DERRIC WOOD | SUBHASH PLACE | 27 | $255.82 | Tablet, SR | Asia |
| 18 | DECINA PHARMA PVT LTD | PUNE | 1 | $246.74 | Injection | Asia |
| 19 | WELCURE REMEDIES | KALA AMB | 1 | $207.68 | Injection | Asia |
| 20 | SUNNY PHARMA | ADIPUR-KUTCH | 1 | $113.67 | Tablet | Americas |
| 21 | ZYPHARS PHARMACEUTICS PVT LTD | PUNE | 3 | $55.92 | Injection | Asia |
| 22 | R.S. SURGIPHARM PVT LTD | AHMEDABAD | 3 | $31.85 | Tablet | Africa |
| 23 | MEDEX PHARMACEUTICALS | KULASEKHARAM POST | 2 | $16.24 | Injection | Asia |
| 24 | SAVA HEALTHCARE LTD | PUNE | 2 | $15.43 | Tablet | Africa |
| 25 | VEA IMPEX (I) PVT LTD | MUMBAI | 4 | $10.02 | Other, 2ML, Solution | Africa |
| 26 | CLOVERLEAF ECOM PVT LTD | NAGPUR | 2 | $8.86 | Tablet | Asia |
| 27 | RMPL PHARMA LLP | MUMBAI | 1 | $7.05 | Injection | Asia |
| 28 | RUTVA MEDICARE | SURAT | 2 | $6.01 | Africa | |
| 29 | BARAKAH BIOHEALTH LLP | Tiruppur | 2 | $3.99 | Injection | Asia |
| 30 | HEMS ( INDIA ) | CHENNAI | 1 | $0.141 | Tablet | Asia |
10
PART VI — EVIDENCE REGISTER
Global Buyer Directory
All 24 global verapamil importers — complete list ranked by USD
KEY TAKEAWAY
This directory lists every company that imported Indian verapamil in 2025-Q4.
S FOR SUPPLIERS
Search for potential customers by country and dosage form.
B FOR BUYERS
Find your company and see which Indian supplier serves you.
| # | Buyer | Country | Ships | USD | Primary supplier | Dosage forms |
|---|---|---|---|---|---|---|
| 1 | GLENMARK PHARMACEUTICALS INC | United States | 19 | $983K | GLENMARK PHARMACEUTI… | Tablet |
| 2 | MYLAN PHARMACEUTICALS INC | United States | 7 | $687K | MYLAN LABORATORIES LTD | Capsule |
| 3 | LIFESCIENCE LOGISTICS | United States | 5 | $528K | CADILA PHARMACEUTICA… | Tablet |
| 4 | BGP PRODUCTS GMBH | Netherlands | 2 | $182K | MYLAN LABORATORIES LTD | Tablet |
| 5 | EVERSANA LIFE SCIENCE SERVICES LLC | United States | 1 | $126K | ZYDUS LIFESCIENCES LTD | Injection |
| 6 | QOMEL COMPANY | Saudi Arabia | 1 | $120K | ZYDUS LIFESCIENCES LTD | Injection |
| 7 | LIFESTAR PHARMA LLC | United States | 3 | $70K | MANKIND PHARMA LTD | Injection |
| 8 | RX CROSSROADS 3PL LLC | United States | 3 | $52K | SOMERSET THERAPEUTIC… | Injection |
| 9 | AVET PHARMACEUTICALS INC | United States | 1 | $51K | STERIL-GENE LIFE SCI… | Injection |
| 10 | VIATRIS PTY LTD | Australia | 4 | $4K | MYLAN LABORATORIES LTD | Tablet |
| 11 | ACTAVIS LLC | United States | 2 | $2K | WATSON PHARMA PVT LTD | Tablet |
| 12 | LABORATORIOS REMENY, C.A | Venezuela | 1 | $1K | KWALITY PHARMACEUTIC… | Tablet |
| 13 | TO THE INVOICE RAISED TO MANGER OF | Barbados | 1 | $605.22 | DRIVECURE HEALTHCARE… | Tablet |
| 14 | AL MAAYER ALASRYAH COMPANY | Saudi Arabia | 1 | $590.47 | SONIA LABORATORY PVT… | Injection |
| 15 | TO THE CONSIGNEE | United Arab Emirates | 5 | $443.85 | ALLEGIANCE PHARMA LLP | Injection |
| 16 | VIATRIS LTD | New Zealand | 1 | $389.19 | MYLAN LABORATORIES LTD | Tablet |
| 17 | EMIRATES POST COMPANY | United Arab Emirates | 27 | $255.82 | DERRIC WOOD | Tablet, SR |
| 18 | IMPERIAL PHOENIX CO LTD | Myanmar | 1 | $246.74 | DECINA PHARMA PVT LTD | Injection |
| 19 | CM STAR CORP | Philippines | 1 | $207.68 | WELCURE REMEDIES | Injection |
| 20 | CENTRAL MEDICAL STORES, MINISTRY OF | Montserrat | 1 | $113.67 | SUNNY PHARMA | Tablet |
| 21 | REGENCY EXIM TRADE LTD | Mauritius | 2 | $15.43 | SAVA HEALTHCARE LTD | Tablet |
| 22 | MEDISUITE MEDICAL STORE | United Arab Emirates | 1 | $12.25 | MEDEX PHARMACEUTICALS | Injection |
| 23 | EMIRATES POST GROUP | United Arab Emirates | 2 | $8.86 | CLOVERLEAF ECOM PVT … | Tablet |
| 24 | BEST INTERNATIONAL FZE | United Arab Emirates | 1 | $4.00 | MEDEX PHARMACEUTICALS | Injection |
This report covers 136 2025-Q4 Verapamil shipments.
TransData Nexus tracks 3.37M+ shipments across all pharmaceuticals since 2020.
→ transdatanexus.com/pharmaceutical/verapamil
Talk to our trade analyst
Need a custom verapamil report or a deeper dive into any market? Our team is ready.
WhatsApp: +91 95950 78788 · transdatanexus.com
PHARMA TRADE INTELLIGENCE
Thank you for reading
This report is part of the TransData Nexus Pharma Trade Intelligence series, covering 366 pharmaceutical products exported from India.
Every figure is grounded in real commercial trade records — official customs filings and licensed databases. No surveys, no estimates, no fake data.
Need a custom report?
We can generate intelligence for any pharmaceutical product, any time period, any combination of source and destination countries.
Want deeper analysis?
Our team provides competitive intelligence, market entry strategy, and supply chain due diligence for pharma importers and exporters.
Scan for product page
WhatsApp: +91 95950 78788
Email: info@transdatanexus.com
Web: https://transdatanexus.com/pharmaceutical/verapamil
© 2026 TransData Nexus. All rights reserved. This report is provided for informational purposes only.
Data sourced from official customs filings and licensed commercial trade databases.
Reproduction without permission is prohibited.
Explore the full Verapamil product page
Live data, supplier directory, price trends, and trade route analysis